Maximizing patient adherence for optimal outcomes in psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue SUPPL. 4, 2011, Pages 9-14

  Bewley, A ^a   Page, B ^b  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^b QUEEN MARGARET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE DIPROPIONATE PLUS CALCIPOTRIOL; CALCIPOTRIOL;

COST OF ILLNESS; DOCTOR PATIENT RELATION; DRUG EFFICACY; HEALTH CARE PERSONNEL; HUMAN; LONG TERM CARE; NURSE; PATIENT COMPLIANCE; PATIENT EDUCATION; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; REVIEW; SELF CONCEPT; STIGMA; SYMPTOM; TREATMENT OUTCOME;

HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT COMPLIANCE; PSORIASIS;

EID: 79955388885     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04060.x     Document Type: Review

References (42)

1. Sabate E, ed. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization, Geneva, 2003.
2. Ali SM, Brodell RT, Balkrishnan R, Feldman SR,. Poor adherence to treatments: a fundamental principle of dermatology. Arch Dermatol 2007; 143: 912-915. (Pubitemid 47076491)
3. Lebwohl M, Ting PT, Koo JY,. Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005; 64 (Suppl. 2): ii83-ii86. (Pubitemid 40288530)
4. Mrowietz U, Reich K,. Psoriasis-new insights into pathogenesis and treatment. Dtsch Arztebl Int 2009; 106: 11-18. quiz 19.
5. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T,. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9: 136-139. (Pubitemid 38457271)
6. Feldman SR,. Approaching psoriasis differently: patient-physician relationships, patient education and choosing the right topical vehicle. J Drugs Dermatol 2010; 9: 908-911.
7. Storm A, Andersen SE, Benfeldt E, Serup J,. One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 2008; 59: 27-33.
8. Zaghloul SS, Goodfield MJ,. Objective assessment of compliance with psoriasis treatment. Arch Dermatol 2004; 140: 408-414. (Pubitemid 38469243)
9. Brown KK, Rehmus WE, Kimball AB,. Determining the relative importance of patient motivations for nonadherence to topical corticosteroid therapy in psoriasis. J Am Acad Dermatol 2006; 55: 607-613. (Pubitemid 44436629)
10. Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE,. Psoriasis patients' compliance with medication. J Am Acad Dermatol 1999; 41: 581-583.
11. Fouéré S, Adjadj L, Pawin H,. How patients experience psoriasis: results from a European survey. J Eur Acad Dermatol Venereol 2005; 19 (Suppl. 3): 2-6. (Pubitemid 41726918)
12. Storm A, Benfeldt E, Andersen SE, Serup J,. A prospective study of patient adherence to topical treatments: 95% of patients underdose. J Am Acad Dermatol 2008; 59: 975-980.
13. Feldman SR, Horn EJ, Balkrishnan R, et al. International Psoriasis Council. Psoriasis: improving adherence to topical therapy. J Am Acad Dermatol 2008; 59: 1009-1016.
14. Richards HL, Fortune DG, Griffiths CE,. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol 2006; 20: 370-379.
15. Hol K,. Patient preference for topical psoriasis formulations. 19th Congress of the European Academy of Dermatology and Venereology (EADV), 6-10 October 2010, Gothenburg, Sweden. P572.
16. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple, practical, measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216. (Pubitemid 24194579)
17. Hahn HB, Melfi CA, Chuang TY, et al. Use of the Dermatology Life Quality Index (DLQI) in a midwestern US urban clinic. J Am Acad Dermatol 2001; 45: 44-48. (Pubitemid 32655691)
18. Kimball AB, Jacobson C, Weiss S, Vreeland MG, Wu Y,. The psychosocial burden of psoriasis. Am J Clin Dermatol 2005; 6: 383-392. (Pubitemid 43128290)
19. Feldman SR, Camacho FT, Krejci-Manwaring J, Carroll CL, Balkrishnan R,. Adherence to topical therapy increases around the time of office visits. J Am Acad Dermatol 2007; 57: 81-83. (Pubitemid 46908856)
20. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV,. Evaluation of topical drug treatment in psoriasis. Dermatology 1998; 197: 31-36. (Pubitemid 28327834)
21. Hol K,. European study into the opinions of psoriasis patients and physicians. 19th Congress of the European Academy of Dermatology and Venereology (EADV), 6-10 October 2010, Gothenburg, Sweden. P573.
22. Zivkovich AH, Feldman SR,. Are ointments better than other vehicles for corticosteroid treatment of psoriasis? J Drugs Dermatol 2009; 8: 570-572.
23. Radtke MA, Augustin M,. Economic considerations in psoriasis management. Clin Dermatol 2008; 26: 424-431.
24. Basra MK, Shahrukh M,. Burden of skin diseases. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 271-283.
25. Navarini AA, Laffitte E, Conrad C, et al. Estimation of cost-of-illness in patients with psoriasis in Switzerland. Swiss Med Wkly 2010; 140: 85-91.
26. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008; 59: 772-780.
27. Zhu TY, Tam LS, Leung YY, et al. Socioeconomic burden of psoriatic arthritis in Hong Kong: direct and indirect costs and the influence of disease pattern. J Rheumatol 2010; 37: 1214-1220.
28. Elliott R,. Non-adherence to medicines: not solved but solvable. J Health Serv Res Policy 2009; 14: 58-61.
29. Rapp SR, Cottrell CA, Leary MR,. Social coping strategies associated with quality of life decrements among psoriasis patients. Br J Dermatol 2001; 145: 610-616.
30. Weiss SC, Rehmus W, Kimball AB,. An assessment of the cost-utility of therapy for psoriasis. Ther Clin Risk Manag 2006; 2: 325-328. (Pubitemid 44349508)
31. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM,. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41 (3 Pt 1): 401-407. (Pubitemid 29418506)
32. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R,. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35.
33. Heydendael VM, de Borgie CA, Spuls PI, Bossuyt PM, Bos JD, de Rie MA,. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc 2004; 9: 131-135. (Pubitemid 38457270)
34. Sampogna F, Gisondi P, Tabolli S, Abeni D, IDI Multipurpose Psoriasis Research on Vital Experiences investigators. Impairment of sexual life in patients with psoriasis. Dermatology 2007; 214: 144-150. (Pubitemid 46377240)
35. Türel Ermertcan A, Temeltaş G, Deveci A, Dinç G, Güler HB, Oztürkcan S,. Sexual dysfunction in patients with psoriasis. J Dermatol 2006; 33: 772-778. (Pubitemid 44630140)
36. Goulding JM, Price CL, Defty CL, Hulangamuwa CS, Bader E, Ahmed I,. Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. Br J Dermatol 2011; 164: 103-109.
37. Fredriksson T, Pettersson U,. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
38. Aaronson NK, Muller M, Cohen PD, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998; 51: 1055-1568.
39. Storm A, Benfeldt E, Andersen SE, Andersen J,. Basic drug information given by physicians is deficient, and patients' knowledge low. J Dermatolog Treat 2009; 20: 190-193.
40. Uhlenhake EE, Kurkowski D, Feldman SR,. Conversations on psoriasis-what patients want and what physicians can provide: a qualitative look at patient and physician expectations. J Dermatolog Treat 2010; 21: 6-12.
41. Gradwell C, Thomas KS, English JS, Williams HC,. A randomized controlled trial of nurse follow-up clinics: do they help patients and do they free up consultants' time? Br J Dermatol 2002; 147: 513-517. (Pubitemid 35015287)
42. Courtenay M, Carey N,. Nurse-led care in dermatology: a review of the literature. Br J Dermatol 2006; 154: 1-6. (Pubitemid 43381313)